The irreversible cost of delayed diagnosis of tuberculosis in HIV co-infected persons in sub-Saharan Africa [1]

International Journal of Tuberculosis and Lung Disease

Volumn 5, Issue 2, 2001, Pages 200-201

  Lawn, S D ^a   Griffin, G E ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; THALIDOMIDE; TUBERCULOSTATIC AGENT;

AFRICA; COMORBIDITY; DEVELOPING COUNTRY; DISEASE COURSE; EARLY DIAGNOSIS; HEALTH CARE COST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDUSTRIALIZATION; LETTER; LUNG TUBERCULOSIS; MORTALITY; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

AFRICA SOUTH OF THE SAHARA; COST OF ILLNESS; HIV INFECTIONS; HUMANS; TIME FACTORS; TUBERCULOSIS;

EID: 0035028997     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Pulmonary tuberculosis: Diagnostic delay in Ghanaian adults
2. Delay in the diagnosis of tuberculosis: A great new cost
3. Pulmonary tuberculosis in adults: Factors associated with mortality at a Ghanaian teaching hospital
4. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation
5. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection
6. Accelerated course of HIV infection after tuberculosis
7. Sustained plasma TNF-α and HIV-1 load despite resolution of other immune activation parameters during treatment for tuberculosis in Africans
8. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: A randomized, controlled trial
9. Persistent elevation of HIV viral load during therapy for tuberculosis
10. Effect of preventive treatment for tuberculosis in adults infected with HIV: Systematic review of randomised placebo controlled trials